Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colgate-Palmolive Co.

www.colgate.com

Latest From Colgate-Palmolive Co.

Colgate Says Hello To Subscription-Delivery Wtih Oral Care Line Acquisition

Colgate agrees to purchase Hello Products direct-to-consumer oral care brand, complementing  its Colgate brand and its Tom’s of Maine natural-positioned line. The firm will pay with a combination of cash and debt in the deal expected to close no later than the end of February.

M & A OTC Drugs

Colgate Launches UK Vegan Toothpaste, Shares Recyclable Tube Technology

Colgate rolls out first recyclable toothpaste tube in UK with launch of Smile for Good. Selling now in retailers including Tesco and Morrisons, the line featuring Protection and Whitening versions is the first toothpaste certified by the Vegan Society.

OTC Drugs Launches

Digital Advances In Consumer Health At CES: Oral Care, Nausea, Beauty Products

OTC drug, supplement and beauty firms are spreading into digital health devices showcased at the 2020 Consumer Electronics Show as technological advancements help consumers reach health and wellness goals. Colgate debuted a smart toothbrush that detects biofilm build-up while L’Oreal introduced AI-powered skin care.

OTC Devices Commercial

US Health Market In 2019: Unfinished Business Leaves Lasting Impression

Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.

OTC Drugs Outlook 2019
See All

Company Information

UsernamePublicRestriction

Register